Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$25.92 -2.8%	$22.84	$12.21 ▼ $41.31	$783.87M	-0.27	649,273 shs	334,038 shs
BCEL Atreca	$0.09	$0.09	$0.05 ▼ $1.20	$3.57M	1.03	4.61 million shs	N/A
CPRX Catalyst Pharmaceuticals	$21.03 -2.0%	$23.23	$15.34 ▼ $26.58	$2.62B	0.66	1.14 million shs	1.23 million shs
FULC Fulcrum Therapeutics	$7.65 -3.7%	$6.91	$2.32 ▼ $10.13	$428.60M	2.37	902,601 shs	397,443 shs
MNK Mallinckrodt		$0.34	$0.75 ▼ $6.42	$1.58M	N/A	2.62 million shs	39,227 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-0.67%	+2.26%	+12.01%	+29.83%	-22.58%
BCEL Atreca	0.00%	0.00%	0.00%	0.00%	0.00%
CPRX Catalyst Pharmaceuticals	+1.27%	-1.83%	-7.62%	-4.75%	+26.92%
FULC Fulcrum Therapeutics	+0.76%	-0.87%	+23.48%	+141.34%	-5.02%
MNK Mallinckrodt	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	1.7273 of 5 stars	3.4	0.0	0.0	0.0	1.6	2.5	0.6
BCEL Atreca	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	4.8975 of 5 stars	3.6	1.0	0.0	3.9	3.0	3.3	3.8
FULC Fulcrum Therapeutics	0.6229 of 5 stars	1.3	2.0	0.0	0.0	2.1	2.5	0.0
MNK Mallinckrodt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	63.48% Upside
BCEL Atreca	0.00	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	56.13% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-17.83% Downside
MNK Mallinckrodt	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MNK, FULC, CPRX, ANAB, and BCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$91.28M	8.34	N/A	N/A	$2.33 per share	11.12
BCEL Atreca	N/A	N/A	N/A	N/A	$2.01 per share	N/A
CPRX Catalyst Pharmaceuticals	$491.73M	5.22	$2.40 per share	8.77	$6.10 per share	3.45
FULC Fulcrum Therapeutics	$80M	5.16	N/A	N/A	$4.51 per share	1.70
MNK Mallinckrodt	N/A	N/A	N/A	N/A	$47.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.85	0.00	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
BCEL Atreca	-$97.16M	-$2.50	N/A	N/A	N/A	N/A	-157.90%	-71.39%	N/A
CPRX Catalyst Pharmaceuticals	$163.89M	$1.57	9.17	9.87	0.87	36.91%	42.45%	36.59%	8/6/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	0.00	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
MNK Mallinckrodt	N/A	-$116.19	N/A	N/A	N/A	-82.59%	20.32%	2.49%	N/A

Latest MNK, FULC, CPRX, ANAB, and BCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	CPRX Catalyst Pharmaceuticals	$0.57	N/A	N/A	N/A	$140.42 million	N/A
8/4/2025	Q2 2025	ANAB AnaptysBio	-$1.47	N/A	N/A	N/A	$11.55 million	N/A
7/30/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
BCEL Atreca	N/A	N/A	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
MNK Mallinckrodt	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.25	8.25
BCEL Atreca	N/A	1.58	1.58
CPRX Catalyst Pharmaceuticals	N/A	6.14	5.96
FULC Fulcrum Therapeutics	N/A	28.71	28.71
MNK Mallinckrodt	1.18	0.57	0.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
BCEL Atreca	37.47%
CPRX Catalyst Pharmaceuticals	79.22%
FULC Fulcrum Therapeutics	89.83%
MNK Mallinckrodt	83.74%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
BCEL Atreca	11.30%
CPRX Catalyst Pharmaceuticals	10.40%
FULC Fulcrum Therapeutics	7.00%
MNK Mallinckrodt	0.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
BCEL Atreca	130	39.62 million	35.15 million	Optionable
CPRX Catalyst Pharmaceuticals	80	121.97 million	109.29 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
MNK Mallinckrodt	2,700	13.17 million	13.13 million	Not Optionable

MNK, FULC, CPRX, ANAB, and BCEL Headlines

Recent News About These Companies

Mallinckrodt's $7B deal to merge with drugmaker Endo advances

June 27, 2025 | bizjournals.com

Mallinckrodt, Endo shareholders approve combination

June 24, 2025 | drugstorenews.comD

Mallinckrodt, Endo announce leadership for merged company

June 18, 2025 | drugstorenews.comD

Mallinckrodt and Endo Shareholders Approve Merger

June 16, 2025 | msn.com

Mallinckrodt and Endo Announce Leadership Plans for Transformative Merger

June 14, 2025 | msn.com

Mallinckrodt plc: Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company

June 9, 2025 | finanznachrichten.de

Mallinckrodt and Endo Advance Key Milestones in Strategic Merger

May 19, 2025 | msn.com

Malvern-Based Endo Progresses Toward Mallinckrodt Merger Completion

May 15, 2025 | msn.com

Mallinckrodt and Endo Announce Significant Progress in Proposed Merger

May 14, 2025 | finance.yahoo.com

Endo, Inc.: Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

May 7, 2025 | finanznachrichten.de

Malvern-Based Endo Approves $3.5M in Retention Bonuses for Executives Ahead of Merger

April 29, 2025 | msn.com

Endo board approves millions in bonuses to keep key execs amid Mallinckrodt merger

April 21, 2025 | bizjournals.com

Mallinckrodt plc to Report Earnings Results for First Quarter 2025

April 10, 2025 | finance.yahoo.com

Malvern’s Endo Enters Into Agreement to Merge with Mallinckrodt in $6 Billion Deal

March 17, 2025 | msn.com

Mallinckrodt, a pharmaceutical giant launched in St. Louis, to take over Endo in $6.7B deal

March 17, 2025 | stltoday.comS

Mallinckrodt and Endo Announce Merger to Build Diversified Pharmaceuticals Powerhouse

March 16, 2025 | msn.com

Mallinckrodt and Endo to combine after emerging from bankruptcy linked to opioid crisis

March 15, 2025 | ft.com

Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal

March 15, 2025 | msn.com

Troubled drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger

March 13, 2025 | biospace.comB

Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal

March 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNK, FULC, CPRX, ANAB, and BCEL Company Descriptions

AnaptysBio NASDAQ:ANAB

$25.92 -0.76 (-2.85%)

Closing price 04:00 PM Eastern

Extended Trading

$25.93 +0.01 (+0.04%)

As of 04:33 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.03 -0.42 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$21.32 +0.29 (+1.38%)

As of 07:35 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Fulcrum Therapeutics NASDAQ:FULC

$7.65 -0.29 (-3.65%)

Closing price 04:00 PM Eastern

Extended Trading

$7.64 -0.01 (-0.07%)

As of 04:04 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Mallinckrodt NYSE:MNK

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time